Anomaly of the des-Arg9-bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: a preliminary study

Transfusion. 1999 Oct;39(10):1084-8. doi: 10.1046/j.1537-2995.1999.39101084.x.

Abstract

Background: Severe hypotensive reactions have been described after the transfusion of platelets or red cells through negatively-charged bedside white cell-reduction filters. The possibility of a role for bradykinin (BK) in the genesis of these reactions has been raised.

Study design and methods: To understand if an anomaly of BK metabolism is associated with these reactions, the metabolism of BK and des-Arg9-BK was studied in the sera of four patients who presented with a severe hypotensive transfusion reaction. Tests were performed in the absence and the presence of complete in vitro inhibition of angiotensin-converting enzyme (ACE) activity by enalaprilat.

Results: In the presence of ACE inhibition (enalaprilat), the half-life (t1/2) of BK measured in the sera of patients who presented with a severe hypotensive transfusion reaction (361 +/- 90 sec) was not significantly different from that measured in the sera of normal controls (249 +/- 16 sec). In the presence of ACE inhibition (enalaprilat), the t1/2 of des-Arg9-BK was significantly greater in patients who presented with a severe hypotensive transfusion reaction (1549 +/- 319 sec) than in normal controls (661 +/- 38 sec) (p < 0.001).

Conclusion: A metabolic anomaly mainly affecting the degradation of des-Arg9-BK could be responsible for its accumulation in vivo. Des-Arg9-BK could be responsible, at least in part, for severe hypotensive transfusion reactions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Aged
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Bradykinin / analogs & derivatives*
  • Bradykinin / blood
  • Enalaprilat / pharmacology
  • Erythrocyte Transfusion / adverse effects*
  • Female
  • Half-Life
  • Humans
  • Hypotension / blood*
  • Hypotension / etiology*
  • Male
  • Middle Aged
  • Peptidyl-Dipeptidase A / blood
  • Platelet Transfusion / adverse effects*

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • bradykinin, des-Arg(9)-
  • Peptidyl-Dipeptidase A
  • Enalaprilat
  • Bradykinin